The center will offer local residents with opportunities and training to enter the pharmacy work force.
CVS Health announced that it is opening a workforce development and community center in Louisiana.1 The center will be located in Baton Rouge and will be focused on improving the area’s access to health service and reducing employment barriers.
According to a press release, the new center will include programs and facilities to help local residents obtain the training they need for employment, along with potential job placement. The center will even include a mock CVS Pharmacy location to be used for training sessions. The center will also be able to provide external training opportunities at nearby CVS Pharmacy locations.
The center will also provide training for CPR and first-aid situations, along with providing connections to loval care providers.
In the press release, Aetna Better Health of Louisiana CEO Jess Hall said, “As a leading health solutions company, we know that there is a strong connection between sustainable employment and health and wellness. With the combined resources of CVS Health and Aetna and our network of community partners, we are uniquely positioned to help the people of Baton Rouge access the career skills training and the health and wellness services they need to overcome barriers to employment, stay healthy and motivated and ultimately succeed in their careers."
Aetna Better Health of Louisiana is a CVS Health company.
In the same press release, mayor-president Sharon Weston Broome said, “I firmly believe in the power of public-private partnerships to drive positive change and create opportunities for our community. The collaboration between Big Buddy Baton Rouge and CVS Health through the Mayor's Youth Workforce Experience (MYWE) exemplifies this commitment, as it provides invaluable workforce development environments and hands-on job training to our future workforce. By working together, we can ensure that our residents have the skills and resources they need to thrive in today's competitive job market. This partnership not only benefits the individuals involved but also strengthens our local economy and fosters a brighter future for Baton Rouge."
The center will also feature a staff of career skills trainers and care navigators. While the center is a new addition to the area, these sorts of programs have been carried out at CVS locations in the area for three years. Local stores participate in both the MYWE and Big Buddy programs, which have allowed local high school students to gain on-the-job experience at participating locations, with the intent that this experience will help them launch a career in the pharmaceutical industry.
"Working at CVS has really helped to strengthen my communication skills, because prior to my externship I was shy, but I've since realized I'm an extrovert," said 16-year-old A'amya Johnson, a MYWE. "I love everything about my job especially talking to the customers. This opportunity has helped me decide that I want to pursue a health care career."
After completing her 2023 summer program, Johnson became a part-time CVS Pharmacy retail associate.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.